CYR-241 / Cyrus Biotech - LARVOL DELTA

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies (Businesswire) - "Cyrus Biotechnology, Inc., today announced data demonstrating potent activity for its engineered IgG-degrading enzyme in a rabbit redosing model, with no anti-drug antibodies (ADAs) evident following repeat administration at therapeutic doses....CYR241 remains highly potent upon a second dose with similar activity to that of the first dose, while the WT enzyme loses potency. The first WT dose rapidly reduces IgG levels, while the second is much less potent, mirroring results seen in the clinic with the WT enzyme and close variants. In contrast, CYR241 lowers IgG levels even further upon a second dose....Cyrus will be attending the 2025 JP Morgan conference in San Francisco and rolling out details of this program and deimmunization methods at the PepTalk conference in San Diego in January."

Preclinical • Immunology